Key Financial Figures - Standalone (in million INR)

Income Statement

  • Revenue from Operations: Q4 FY26: ₹3,615.73; FY26: ₹13,414.76 (FY25: ₹11,743.74)
  • Other Income, net: Q4 FY26: ₹274.75; FY26: ₹1,035.33 (FY25: ₹657.87)
  • Total Income: Q4 FY26: ₹3,890.48; FY26: ₹14,450.09 (FY25: ₹12,401.61)
  • Profit Before Tax: Q4 FY26: ₹1,243.58; FY26: ₹3,915.43 (FY25: ₹2,432.59)
  • Total Tax Expense: Q4 FY26: ₹324.35; FY26: ₹908.45 (FY25: ₹549.87)
  • Profit After Tax: Q4 FY26: ₹919.23; FY26: ₹3,006.98 (FY25: ₹1,882.72)
  • Earnings Per Share (Basic): Q4 FY26: ₹2.03; FY26: ₹6.64 (FY25: ₹4.15)
  • Earnings Per Share (Diluted): Q4 FY26: ₹2.03; FY26: ₹6.63 (FY25: ₹4.15)

Balance Sheet (as of March 31, 2026)

  • Total Assets: ₹19,940.29 million (FY25: ₹17,553.02 million)
  • Equity Share Capital: ₹453.16 million (unchanged from FY25)
  • Other Equity: ₹16,069.94 million (FY25: ₹13,381.70 million)
  • Total Equity: ₹16,523.10 million (FY25: ₹13,834.86 million)
  • Current Assets: ₹13,090.78 million (including Cash & Cash Equivalents: ₹912.50 million)
  • Inventories: ₹1,891.30 million
  • Trade Receivables: ₹6,234.62 million

Cash Flow Statement (FY26)

  • Net Cash from Operating Activities: ₹2,110.86 million
  • Net Cash from Investing Activities: ₹(1,402.92) million
  • Net Cash from Financing Activities: ₹(392.33) million
  • Net Increase in Cash: ₹315.61 million

Key Financial Figures - Consolidated (in million INR)

Income Statement

  • Revenue from Operations: Q4 FY26: ₹8,561.14; FY26: ₹29,509.38 (FY25: ₹26,228.45)
  • Other Income, net: Q4 FY26: ₹351.74; FY26: ₹825.33 (FY25: ₹663.29)
  • Profit Before Tax: Q4 FY26: ₹1,999.98; FY26: ₹5,605.55 (FY25: ₹5,039.67)
  • Profit After Tax: Q4 FY26: ₹1,490.32; FY26: ₹4,200.64 (FY25: ₹3,826.19)
  • Net Profit Attributable to Owners: Q4 FY26: ₹1,481.29; FY26: ₹4,179.00 (FY25: ₹3,805.75)
  • Earnings Per Share (Basic & Diluted): Q4 FY26: ₹3.27; FY26: ₹9.22 (FY25: ₹8.40)

Balance Sheet (as of March 31, 2026)

  • Total Assets: ₹38,609.02 million
  • Equity Attributable to Owners: ₹30,231.56 million
  • Non-Controlling Interests: ₹295.24 million
  • Total Equity: ₹30,526.80 million
  • Inventories: ₹9,722.81 million
  • Trade Receivables: ₹6,445.66 million
  • Cash & Cash Equivalents: ₹6,341.37 million

Subsidiary Information

The consolidated results include 15 subsidiaries, with 12 being audited and 3 unaudited (considered immaterial). Key subsidiaries include Marksans Pharma Inc., Time-Cap Laboratories Inc., Nova Pharmaceuticals Australasia Pty Ltd (60% holding), and newly formed Marksans Pharma (Europe) Limited and Marksans (Canada) Inc.

Operational Highlights

  • Net Foreign Exchange Gain: Standalone FY26: ₹474.26 million; Consolidated FY26: ₹500.95 million
  • Employee Stock Options: Granted 400,000 equity stock options on September 24, 2025, under Marksans Employees Stock Option Scheme 2024
  • Labour Code Impact: Net impact of ₹26.09 million recognized as Employee Benefits Expense due to implementation of new Labour Codes
  • New Subsidiaries: Formed Marksans Pharma (Europe) Limited (Ireland) on January 16, 2026, and Marksans (Canada) Inc. on January 22, 2026

Dividend Information

The Board of Directors recommended a final dividend of ₹0.90 per equity share (90%) for Financial Year 2025-26.